Advertisement
Nate Diaz and Conor McGregor pictured after their bout at UFC 202 in Las Vegas on 20 August. Isaac Brekken
warning

Diaz gets slap on the wrist for using 'prohibited substance' CBD after McGregor loss

USADA has issued a public warning to the UFC star.

NATE DIAZ HAS been given a public warning as a result of his use of cannabidiol [CBD] oil in the aftermath of his recent defeat to Conor McGregor.

Diaz ‘vaped’ CBD during the post-fight press conference following his majority-decision loss to the Dubliner at UFC 202 at the T-Mobile Arena in Las Vegas on 20 August.

The use of cannabidol is prohibited in competition by the World Anti-Doping Agency [WADA], whose list of prohibited substances is adopted by the United States Anti-Doping Agency [USADA], which is employed by the UFC to police its anti-doping policy.

“It’s CBD,” Diaz said during the press conference. “It helps with the healing process and inflammation — stuff like that. You want to get these for before and after the fight, training. It’ll make your life a better place.”

MassRoots / YouTube

In a statement released last night, USADA explained that a public warning — which Diaz has accepted — instead of a suspension was deemed “an appropriate response” to the violation as the California native mistakenly believed that the in-competition period ended after he provided a post-bout sample to USADA.

‘In competition’ is defined as the period beginning six hours prior to the scheduled weigh-in — the day before the fight — and ending six hours after the fight itself. The in-competition urine and blood samples provided by Diaz before his admitted use were analysed and reported as negative for all prohibited substances, including cannabidiol.

Cormier will defend light heavyweight title with UFC 206 rematch against Johnson

Quiz: Can you identify these UFC fighters from their records alone?

Your Voice
Readers Comments
4
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.